Loading...

BCDA BIOCARDIA INC Delisting Actions 8-K Filing

BCRD

BCD

BIOCARDIA INC

(BCDA)

2025 8-K

Financial Results Announcement

Clinical Trial Announcement

Trial Enrollment Announcement

Annual Meeting Notice

Compliance Regained

Compliance Update

Positive Meeting Outcomes

Stock Offering Details

Stock Offering Announcement

CardiAMP Results Update

New Partnership Agreement

Product Expansion

Clinical Trials

Geographic Expansion

Equity Offerings

Other Special Situation

Financial Statements

New Product Launches

Clinical Trials

Equity Offerings

Trial Enrollment

Nasdaq Compliance

Conference Call

Clinical Trial Results

Financial Results

Trial Enrollment Complete

Conference Presentation

Regulatory Update

Financial Results

Clinical Trial Update

Nasdaq Compliance

Public Offering

Public Offering

Financial Results

Patent Issuance

Collaborative Phase II Tria...

Patent Issuance

Reverse Stock Split

Annual Meeting and Reverse ...

Financial Results Announcement

Financial Results Announcement

Partnership Announcement

Other Special Situation

Announcement of Positive In...

Private Placement

Announcement of Scientific ...

At The Market Offering Agre...

Update on Stockholder Advis...

Extension of Proposal Deadline

Update on CardiAMP autologo...

Securities Purchase Agreement

FDA Approval for Phase III ...

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Reports

Product Updates

Market Expansion

Termination of Agreement an...

Securities Purchase Agreement

Suspension of Sales

FDA Review Completion for C...

Financial Results Announcement

Patent Issuance

Amended Bylaws Approval

Announcement of Presentations

Patent Issuance

External Links:

BioCardia, Inc. announced on October 2, 2025, that it has regained compliance with Nasdaq's Listing Rule 5550(b)(1), allowing its common stock to remain listed on the Nasdaq Stock Market.

AI Assistant

BIOCARDIA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.